Abolon was the exclusive adviser to The Rohatyn Group ("TRG"), an emerging markets focused asset management firm, on its investment in Amethyst Radiotherapy, obtaining co-control of the Company alongside the two co-founders. Amethyst is one of the largest operators of radiotherapy clinics in Europe and provides radiotherapy treatment for most types of common cancers. The transaction was announced yesterday. Amethyst operates centres across France, Romania, Italy, Poland and Austria, treating over 10,000 patients annually. TRG’s investment will be used to accelerate the growth of the Company across Europe through the roll-up of clinics, the development of greenfield centres and outsourcing partnerships with hospitals. Radiation therapy (also called radiotherapy) is a cancer treatment that uses high doses of radiation to kill cancer cells and/or to slow down their growth by damaging their DNA. Abolon served TRG with a dedicated team of its specialised advisers, building on numerous projects in the broader radiotherapy & radiology space during recent years.
The new Hospital Structure Act could force small, low quality public sector hospitals to the wall. But it could also cap growth for big private operators. We examine likely scenarios.
The Deal: In December 2015, Etac, a Sweden-based developer and manufacturer of mobility solutions and rehab products, acquired Convaid Products
Abolon is a strategy consulting and corporate finance company with an exclusive focus on the healthcare sector.
We pride ourselves on our specialist insights into the various segments of the healthcare markets in Europe and beyond.
Our global network in the healthcare sector provides us with unmatched dealflow of large and mid-sized healthcare opportunities.